- Home
- ADSE vs PLRX Comparison
ADSE vs PLRX Comparison
Compare ADSE & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- PLRX
- Stock Information
- Founded
- ADSE 1980
- PLRX 2015
- Country
- ADSE Ireland
- PLRX United States
- Employees
- ADSE N/A
- PLRX N/A
- Industry
- ADSE Industrial Specialties
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- PLRX Health Care
- Exchange
- ADSE Nasdaq
- PLRX Nasdaq
- Market Cap
- ADSE 728.1M
- PLRX 641.5M
- IPO Year
- ADSE N/A
- PLRX 2020
- Fundamental
- Price
- ADSE $13.24
- PLRX $12.43
- Analyst Decision
- ADSE Hold
- PLRX Strong Buy
- Analyst Count
- ADSE 1
- PLRX 7
- Target Price
- ADSE $14.00
- PLRX $40.50
- AVG Volume (30 Days)
- ADSE 93.5K
- PLRX 418.7K
- Earning Date
- ADSE 09-12-2024
- PLRX 11-07-2024
- Dividend Yield
- ADSE N/A
- PLRX N/A
- EPS Growth
- ADSE N/A
- PLRX N/A
- EPS
- ADSE N/A
- PLRX N/A
- Revenue
- ADSE $158,974,606.00
- PLRX N/A
- Revenue This Year
- ADSE $98.67
- PLRX N/A
- Revenue Next Year
- ADSE $47.66
- PLRX $585.71
- P/E Ratio
- ADSE N/A
- PLRX N/A
- Revenue Growth
- ADSE 168.42
- PLRX N/A
- 52 Week Low
- ADSE $6.10
- PLRX $10.22
- 52 Week High
- ADSE $15.01
- PLRX $19.62
- Technical
- Relative Strength Index (RSI)
- ADSE 43.56
- PLRX 37.61
- Support Level
- ADSE $13.18
- PLRX $13.55
- Resistance Level
- ADSE $14.33
- PLRX $15.85
- Average True Range (ATR)
- ADSE 0.70
- PLRX 0.94
- MACD
- ADSE -0.14
- PLRX -0.33
- Stochastic Oscillator
- ADSE 14.58
- PLRX 15.44
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.